Historical Valuation
Phathom Pharmaceuticals Inc (PHAT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.02 is considered Undervalued compared with the five-year average of -4.12. The fair price of Phathom Pharmaceuticals Inc (PHAT) is between 348.38 to 353.59 according to relative valuation methord. Compared to the current price of 15.60 USD , Phathom Pharmaceuticals Inc is Undervalued By 95.52%.
Relative Value
Fair Zone
348.38-353.59
Current Price：15.60
95.52%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Phathom Pharmaceuticals Inc (PHAT) has a current Price-to-Book (P/B) ratio of -2.64. Compared to its 3-year average P/B ratio of -1.48 , the current P/B ratio is approximately 78.30% higher. Relative to its 5-year average P/B ratio of -2.22, the current P/B ratio is about 18.98% higher. Phathom Pharmaceuticals Inc (PHAT) has a Forward Free Cash Flow (FCF) yield of approximately -20.60%. Compared to its 3-year average FCF yield of -36.69%, the current FCF yield is approximately -43.85% lower. Relative to its 5-year average FCF yield of -31.83% , the current FCF yield is about -35.29% lower.
P/B
Median3y
-1.48
Median5y
-2.22
FCF Yield
Median3y
-36.69
Median5y
-31.83
Competitors Valuation Multiple
AI Analysis for PHAT
The average P/S ratio for PHAT competitors is 382.70, providing a benchmark for relative valuation. Phathom Pharmaceuticals Inc Corp (PHAT.O) exhibits a P/S ratio of 4.02, which is -98.95% above the industry average. Given its robust revenue growth of 202.74%, this premium appears sustainable.
Performance Decomposition
AI Analysis for PHAT
1Y
3Y
5Y
Market capitalization of PHAT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PHAT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PHAT currently overvalued or undervalued?
Phathom Pharmaceuticals Inc (PHAT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.02 is considered Undervalued compared with the five-year average of -4.12. The fair price of Phathom Pharmaceuticals Inc (PHAT) is between 348.38 to 353.59 according to relative valuation methord. Compared to the current price of 15.60 USD , Phathom Pharmaceuticals Inc is Undervalued By 95.52% .
What is Phathom Pharmaceuticals Inc (PHAT) fair value?
PHAT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Phathom Pharmaceuticals Inc (PHAT) is between 348.38 to 353.59 according to relative valuation methord.
How does PHAT's valuation metrics compare to the industry average?
The average P/S ratio for PHAT's competitors is 382.70, providing a benchmark for relative valuation. Phathom Pharmaceuticals Inc Corp (PHAT) exhibits a P/S ratio of 4.02, which is -98.95% above the industry average. Given its robust revenue growth of 202.74%, this premium appears sustainable.
What is the current P/B ratio for Phathom Pharmaceuticals Inc (PHAT) as of Jan 10 2026?
As of Jan 10 2026, Phathom Pharmaceuticals Inc (PHAT) has a P/B ratio of -2.64. This indicates that the market values PHAT at -2.64 times its book value.
What is the current FCF Yield for Phathom Pharmaceuticals Inc (PHAT) as of Jan 10 2026?
As of Jan 10 2026, Phathom Pharmaceuticals Inc (PHAT) has a FCF Yield of -20.60%. This means that for every dollar of Phathom Pharmaceuticals Inc’s market capitalization, the company generates -20.60 cents in free cash flow.
What is the current Forward P/E ratio for Phathom Pharmaceuticals Inc (PHAT) as of Jan 10 2026?
As of Jan 10 2026, Phathom Pharmaceuticals Inc (PHAT) has a Forward P/E ratio of -12.29. This means the market is willing to pay $-12.29 for every dollar of Phathom Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Phathom Pharmaceuticals Inc (PHAT) as of Jan 10 2026?
As of Jan 10 2026, Phathom Pharmaceuticals Inc (PHAT) has a Forward P/S ratio of 4.02. This means the market is valuing PHAT at $4.02 for every dollar of expected revenue over the next 12 months.